EMA updates on Brexit and clinical trials overhaul

The management board of the European Medicines Agency has provided a statement with highlights from its December 2017 meeting, including a look ahead to the agency’s agenda for next year.

After the Netherlands was  selected to become the new host for the agency post-Brexit, the EMA says it began working immediately to plan for the transition, with “plans to progress activities relating to the temporary and permanent premises, staff relocation, financial and legal aspects, and external communication.”

The EMA has also developed a methodology with the European Union for the redistribution of the work currently carried out by the UK’s regulatory agencies, details of which will be communicated early next year.